Drug intelligence / Profile preview

CoVacHGMix

Development stage: Phase 1
Lead developer: Ankara City Hospital Bilkent
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**CoVacHGMix** is an investigational SARS-CoV-2 vaccine composed of an equal-volume mixture of four type 5 adenoviral-vector components: CoVacHGA1320, CoVacHGB420, CoVacHGC720, and CoVacHGD1480. It is intended to prevent COVID-19 by eliciting antiviral immune responses to SARS-CoV-2 antigens delivered by the adenoviral vectors. Ankara City Hospital Bilkent registered a randomized, double-blind Phase I study evaluating two intramuscular dose volumes administered 28 days apart in healthy adults. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05526183))

Beyond the preview

Go deeper on CoVacHGMix.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CoVacHGMix.

Explore the full profile